FDA Class II Recall: Rising Pharma's Carbidopa, Levodopa, Entacapone Tablets Face Mix-Up
Rising Pharma Holdings, Inc. has initiated a Class II recall for Carbidopa, Levodopa, Entacapone Tablets (25 mg/100 mg/200 mg) due to a product mix-up. Bottles labeled for a lower strength were found to contain a higher strength (37.5 mg/150 mg/200 mg) manufactured by Suven Pharmaceuticals Limited. This event highlights critical supply chain quality control vulnerabilities for procurement and regulatory teams.
FDA Class II Recall: Rising Pharma's Carbidopa, Levodopa, Entacapone Product Mix-Up
Rising Pharma Holdings, Inc., based in East Brunswick, NJ, has initiated a voluntary, firm-initiated Class II recall for specific lots of its Carbidopa, Levodopa, and Entacapone Tablets. The recall, identified as D-0029-2026 and initiated on October 7, 2025, stems from a critical product mix-up. A complaint revealed that sealed 100-count bottles, explicitly labeled as the 25 mg/100 mg/200 mg strength (NDC# 16571-691-01), actually contained film-coated tablets of a higher strength: 37.5 mg/150 mg/200 mg. This mislabeling affects 2,064 100-count bottles from Lot #CS25070, with an expiration date of March 31, 2027. The distribution pattern for these affected products is nationwide across the USA. For procurement directors, this event necessitates an immediate audit of current inventory for Carbidopa, Levodopa, and Entacapone, specifically targeting the identified NDC and lot number. The Class II classification indicates that exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, the commercial implications of managing such a recall, including reverse logistics and potential product shortages, are significant for any business involved in the supply chain.
Manufacturing Origin and Global Supply Chain Vulnerability
The recalled Carbidopa, Levodopa, and Entacapone Tablets, while marketed by Rising Pharma Holdings, Inc. from East Brunswick, NJ, were manufactured by Suven Pharmaceuticals Limited, located in Pashamylaram, Telangana, India. This highlights the inherent complexities and potential vulnerabilities within global pharmaceutical supply chains, particularly concerning contract manufacturing organizations (CMOs). For supply chain VPs and business development executives, this incident underscores the critical importance of rigorous vendor qualification and continuous oversight of overseas manufacturing partners. A product mix-up at the manufacturing site in India, leading to mislabeled products distributed nationwide in the USA, demonstrates a potential lapse in quality control systems at the point of production or packaging. This event necessitates a re-evaluation of current due diligence processes for CMOs, focusing on their adherence to Good Manufacturing Practices (GMP) and their internal quality assurance protocols. Reliance on a single manufacturing site for critical drug components or finished products, especially in a geographically distant location, can expose businesses to significant regulatory and supply disruption risks, demanding robust contingency planning and diversification strategies.
Commercial Impact and Patient Safety Implications for Parkinson's Treatment
Carbidopa, Levodopa, and Entacapone is a critical combination medication used in the management of Parkinson's disease, targeting symptoms by increasing dopamine levels in the brain. The product mix-up, where patients could inadvertently receive a higher strength (37.5 mg/150 mg/200 mg) instead of the prescribed lower strength (25 mg/100 mg/200 mg), carries significant patient safety implications. Higher doses of these active pharmaceutical ingredients (APIs) can lead to increased side effects such as dyskinesia, nausea, hallucinations, or orthostatic hypotension, potentially exacerbating the patient's condition or causing new adverse events. For regulatory affairs heads, this raises concerns about pharmacovigilance and the potential for adverse event reporting, necessitating clear communication channels with healthcare providers and patients. Pharmacies and hospitals nationwide must ensure immediate quarantine of the affected lot (CS25070) to prevent dispensing errors. Business development executives should recognize the potential for reputational damage and erosion of trust among healthcare professionals and patients, emphasizing the need for transparent and swift recall management to mitigate long-term commercial repercussions in the competitive Parkinson's treatment market.
Regulatory Scrutiny and Future Compliance Outlook for Rising Pharma
The FDA's classification of this event as an 'Ongoing' Class II recall signals continued regulatory oversight on Rising Pharma Holdings, Inc. and its manufacturing partner, Suven Pharmaceuticals Limited. While the recall was voluntarily initiated by the firm, the underlying product mix-up indicates a failure in quality control systems that the FDA will expect to be thoroughly investigated and remediated. Regulatory affairs heads should anticipate heightened scrutiny, potentially leading to further inspections of both Rising Pharma's operations and Suven Pharmaceuticals' facility in India. The FDA will require a comprehensive root cause analysis and the implementation of robust corrective and preventive actions (CAPA) to prevent recurrence. Failure to adequately address these issues could escalate to more severe enforcement actions, such as an FDA Warning Letter or even an Import Alert for products originating from Suven Pharmaceuticals, which would have profound implications for supply continuity. Procurement directors must consider the potential for future supply disruptions from this manufacturer and begin evaluating alternative sourcing strategies to safeguard against regulatory non-compliance risks impacting product availability.
Broader Industry Challenges in Pharmaceutical Quality Control
This incident involving Rising Pharma Holdings, Inc. is not an isolated event but rather reflects broader, persistent challenges in pharmaceutical quality control across the industry. Recent parallel events, such as the FDA Class II recall of Essential Wellness Pharma's Progesterone Injection in June 2026 due to sterility assurance failures, underscore a recurring pattern of quality system deficiencies. For senior decision-makers, these incidents highlight the imperative for robust quality management systems that extend beyond internal operations to encompass the entire supply chain, especially when engaging with contract manufacturers. Procurement directors must integrate comprehensive quality audits and performance metrics into their supplier selection and ongoing management processes, moving beyond mere cost considerations. Regulatory affairs heads should leverage these industry trends to reinforce internal compliance training and ensure proactive adherence to cGMP standards. The cumulative effect of such recalls can erode public trust in generic pharmaceutical products and lead to increased regulatory burden, impacting market access and operational costs for all industry players. Proactive investment in quality infrastructure and supply chain resilience is paramount to navigate this evolving regulatory landscape.